
ASM Microbe: GeoVax present single-dose vaccines for Ebola, Lassa and Zika
At ASM Microbe GeoVax have spoken on the development of single-dose vaccines for emerging diseases using their MVA ‘Plug and Play’ platform technology.
At ASM Microbe GeoVax have spoken on the development of single-dose vaccines for emerging diseases using their MVA ‘Plug and Play’ platform technology.
Researchers have uncovered structural and functional details of a key Lassa virus protein; this new information may aid the development of vaccines and therapeutics in the future.
Editor, Martha Powell, takes a closer look at MERS, Nipah and Lassa; considering their impact on populations thus far and why medical countermeasures against them are so urgently required.